ADORA2A and myeloid sarcoma: On the basis of the above evidence, it appears that central A2AR and A2BR activation are deleterious in MS and its preclinical counterpart EAE but, at the same time, peripheral A2AR‐mediated anti‐inflammatory effects should be preserved by opportune drug delivery, that is, by intranasal administration.